Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: Should unstable angina be included in the primary end point?

Diabetes Care

Volumn 40, Issue 9, 2017, Pages 1144-1151

  Marx, Nikolaus ^a   McGuire, Darren K ^b   Perkovic, Vlado ^c   Woerle, Hans Juergen ^d   Broedl, Uli C ^d   Von Eynatten, Maximilian ^d   George, Jyothis T ^d   Rosenstock, Julio ^e  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e Dallas Diabetes and Endocrine Center at Medical City   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

BIOASSAY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); HOSPITALIZATION; HUMAN; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; ENDPOINT DETERMINATION; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 85028091172     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-0068     Document Type: Article

References (48)

1. Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetesmellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-841
2. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014;383:2008-2017
3. Zinman B, Wanner C, Lachin JM, et al.; EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
4. U.S. Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes [Internet], 2 December 2016. Silver Spring,MD, U.S. Food and Drug Administration. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Accessed 15 May 2017
5. Jardiance (empagliflozin) prescribing information [Internet], December 2016. Ridgefield, CT, Boehringer Ingelheim Pharmaceuticals, Inc., and Indianapolis IN, Eli Lilly and Company. Available f rom http://www.accessdata.fda.gov/drugsatfda-docs/label/2016/204629s008lbl.pdf.
6. European Medicines Agency Committee for Medicinal Products for Human Use. Summary of opinion (post authorisation): Jardiance (empagliflozin) [Internet], 15 December 2016 (EMA/398392/2016). Available from http://www.ema .europa.eu/ema/pages/includes/document/open- document.jsp?webContentId5WC500218154. Accessed 15 May 2017
7. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl JMed 2016;375: 311-322
8. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844
9. Ferreira-González I, Busse JW, Heels-Ansdell D, et al. Problems with use of composite end points in cardiovascular trials: systematic reviewof randomised controlled trials. BMJ 2007;334:786
10. Tomlinson G, Detsky AS. Composite end points in randomized trials: there is no free lunch. JAMA 2010;303:267-268
11. GBD 2013Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-171
12. Butala NM, Johnson BK, Dziura JD, et al. Decade-long trends in mortality among patients with and without diabetes mellitus at a major academic medical center. JAMA Intern Med 2014; 174:1187-1188
13. Desai JR, Vazquez-Benitez G, Xu Z, et al.; SUPREME-DMStudy Group.Who must we target nowtominimize future cardiovascular events and total mortality? Lessons from the Surveillance, Prevention andManagement of DiabetesMellitus (SUPREME-DM) cohort study. Circ Cardiovasc Qual Outcomes 2015;8:508-516
14. Harding JL, Shaw JE, Peeters A, Davidson S, Magliano DJ. Age-specific trends from2000-2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people. Diabetes Care 2016;39:1018-1026
15. Lind M, Garcia-Rodriguez LA, Booth GL, et al. Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia 2013;56:2601-2608
16. Tierney EF, Cadwell BL, Thompson TJ, et al. Reductions in excess mortality rates among people with diabetes by selected cause of death. J Diabetes Complications 2009;23:77-82
17. Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017;376: 1407-1418
18. Center for Drug Evaluation and Research. Guidance for industry. Diabetes mellitusdevaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet], December 2008. Silver Spring, MD, U.S. Food and Drug Administration. Available fromhttp://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed 15 May 2017
19. Pocock SJ, Clayton TC, StoneGW. Challenging issues in clinical trial design: part 4 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol 2015;66:2886-2898
20. Mannucci E, Mosenzon O, Avogaro A. Analyses of results fromcardiovascular safety trials with DPP-4 inhibitors: cardiovascular outcomes, predefined safety outcomes, and pooled analysis and meta-analysis. Diabetes Care 2016;39(Suppl. 2): S196-S204
21. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
22. Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289
23. Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol 2015;66:403-469
24. Holmvang L, Hasbak P, Clemmensen P, Wagner G, Grande P. Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction( a Thrombin InhibitioninMyocardial Ischemia [TRIM] substudy). Am J Cardiol 1998;82:54-60
25. Näslund U, Grip L, Fischer-Hansen J, Gundersen T, Lehto S, Wallentin L. The impact of an end-point committee in a largemulticentre, randomized, placebo-controlled clinical trial: resultswith and without the end-point committee's final decision on end-points. Eur Heart J 1999;20: 771-777
26. Heckbert SR, Kooperberg C, Safford MM, et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol 2004;160:1152-1158
27. RoffiM, Patrono C, Collet JP, et al.; Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESCGuidelines for themanagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315
28. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014;2:843-851
29. Standl E, Schnell O,McGuire DK. Heart failure considerations of antihyperglycemic medications for type 2 diabetes. Circ Res 2016;118:1830-1843
30. AstraZeneca. AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure [Internet], 12 September 2016. Available from https://www .astrazeneca.com/media-centre/press-releases/2016/astrazeneca-announces-two-new-phase-IIIb-trials-for-Forxiga-in-chronic-kidney-diseaseand-chronic-heart-failure-120920161.html. Accessed 15 May 2017
31. Boehringer Ingelheim. Jardiance (empagliflozin) to be studied for the treatment of people with chronic heart failure [Internet], 19 April 2016. Available from https://www.boehringer-ingelheim .com/press-release/jardiance-empagliflozin-bestudied-treatment-people-chronic-heart-failure. Accessed 15 May 2017
32. Center for Biologics Evaluation and Research. Multiple endpoints in clinical trials: guidance for industry (draft guidance) [Internet], January 2017. Silver Spring, MD, U.S. Food and Drug Administration. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM536750.pdf. Accessed 15 May 2017
33. Pocock SJ, StoneGW. The primary outcome is positivedis that good enough? N Engl J Med 2016;375:971-979
34. Center for Drug Evaluation and Research. Meeting expectations to exclude a CV risk margin of 1.3. In Application number: 204042Orig1s000 summary review [Internet], March 2013, p.20 Available from https://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/204042Orig1s000SumR.pdf. Accessed 15 May 2017
35. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-2192
36. European Medicines Agency Committee for Medicinal Products for Human Use. Reflection paper on assessment of cardiovascular safety profile of medicinal products [Internet], 25 February 2016 (EMA/CHMP/50549/2015). Available from www.ema.europa.eu/ema/pages/includes/document/open-document .jsp?webContentId5WC500203804. Accessed 15 May 2017
37. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose loweringin type 2 diabetes. N Engl J Med 2008;358:2545-2559
38. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
39. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358: 2560-2572
40. Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-386
41. Frye RL, August P, BrooksMM, et al.; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-2515
42. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia.N Engl J Med 2012;367:319-328
43. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
44. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
45. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-2257
46. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
47. ClinicalTrials.gov. A study to evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650 [Internet]. Available from https://clinicaltrials.gov/ct2/show/NCT01455896. Accessed 19 October 2016
48. Zannad F, Cannon CP, Cushman WC, et al.; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385:2067-2076